Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

This is a randomized, double-blind, placebo-controlled Phase 2 study, which improves interpretability, and the endpoint is clinically relevant: UEMS directly measures arm and hand motor function in cervical SCI, the most meaningful functional domain for this population. But the setup is still unfavorable for a clear positive readout. Acute traumatic cervical SCI is heterogeneous, with large spontaneous recovery variability and dependence on injury severity, timing, and supportive care. The trial is very small at roughly 54 participants, so modest baseline imbalances can overwhelm signal and make effect estimates noisy. Operational execution is also tough: treatment must start within 24 hours of injury, dosing continues for 48 weeks, and about one patient per site is implied across 49 global sites, increasing protocol inconsistency. A 52-week efficacy endpoint gives recovery time but also adds attrition and rehabilitation-related noise. The mechanism is interesting, but the trial fields provide no strong prior human efficacy signal to offset the historical difficulty of SCI neurorecovery studies.

Elezanumab failed both Phase 2 MS trials (RADIUS-R and RADIUS-P), missing the primary ORS endpoint at week 52 across relapsing and progressive populations with no benefit on any exploratory endpoint or biomarker. While acute traumatic SCI is mechanistically distinct from chronic neurodegeneration in MS—and NHP SCI preclinical data showed meaningful locomotor improvement—the complete absence of neurorestorative signal in two adequately powered MS studies substantially undercuts confidence in anti-RGMa clinical translation. The SCI trial enrolled only ~54 patients with severe cervical AIS A/B injuries, a population with high spontaneous recovery variability that makes signal detection difficult in small samples. The trial completed by January 2026 with a ClinicalTrials.gov update in February 2026, but no results have been publicly disclosed, which is neutral but does not suggest a rush to announce positive data. Phase 2 CNS base rates are ~20%, further depressed here by the cross-indication failure. Orphan Drug and Fast Track designations reflect unmet need, not efficacy evidence.

This is a Phase 2 trial for elezanumab in acute traumatic cervical SCI, a notoriously difficult indication where neurological recovery is extremely challenging. The mechanism—neutralizing an inhibitor of neuronal regeneration—is scientifically interesting but unproven in human SCI. Phase 2 trials in neurological recovery typically face high failure rates, and the sample size (~54 participants) provides limited statistical power. While AbbVie is a major sponsor with resources, the baseline probability for positive Phase 2 SCI trials is low. The primary endpoint (UEMS change at 52 weeks) is clinically meaningful but difficult to achieve in acute cervical injury. Given these factors, intrinsic YES odds are estimated around 30-40%, well below even probability.

The trial is a Phase 2 study in acute traumatic cervical SCI, a severe injury with high unmet need. The primary endpoint is Upper Extremity Motor Score (UEMS) change at 52 weeks. While the sponsor (AbbVie) is capable and the trial is completed, intrinsic success odds appear low. The mechanism, a monoclonal antibody targeting a neurite outgrowth inhibitor, is plausible but unproven for meaningful functional recovery in humans. The small sample size (~54 participants) increases statistical noise and risk. Furthermore, the 1:2 placebo:active randomization is unusual for a small study and may complicate interpretation. The primary completion date has passed, but no data has been disclosed, introducing disclosure risk. Historical failure rates in neuro-recovery trials are high. A positive result requires a robust signal on a challenging motor endpoint.

Phase 2 double-blind placebo-controlled trial (2:1 ratio, n=54) in acute traumatic cervical SCI patients aged 18-75, dosed IV elezanumab within 24h of injury and q4w through wk48 (13 doses). Primary endpoint: UEMS change at 52w, validated objective motor score (0-50 bilateral upper limbs); secondary safety AEs to 91w. Patient pop homogeneous (cervical level, recent injury optimal for regen intervention). Endpoint quality high but SCI high variability (injury severity, surgery, rehab confound). ~36/arm small, underpowered for modest effects (e.g., delta 2-4 pts, SD 8-12 needs n>100/arm for 80% power @alpha=0.05). No prior elezanumab SCI data; novel mAb neutralizing regen inhibitor promising preclin but neuro field risky. AbbVie strong execution, 49 global sites aid enrollment/retention in rare disease. Trial completed Jan 2026, data mature, low disclosure risk. SCI Ph2 success <15% historically (high placebo, failures like NVG-291, riluzole marginal Ph3). Intrinsic P(sig UEMS win) 25%.

The trial evaluates Elezanumab in acute cervical SCI, a notoriously difficult indication with a history of neuroregeneration failures. While the mechanism (inhibiting a neural regeneration blocker) is scientifically sound, the trial design raises concerns. The sample size is small (N=54), limiting statistical power to detect efficacy on the continuous UEMS endpoint. Additionally, the 2:1 randomization (drug:placebo) complicates variance estimation. Crucially, the primary completion date passed in Jan 2026, yet no results are posted by Apr 2026. This delay often signals inconclusive or negative findings, as sponsors typically publicize positive Phase 2 data rapidly to support Phase 3 planning. Given the high risk of failure in SCI and the ominous silence post-completion, intrinsic probability of a positive result is assessed as low.

Phase 2 SCI trial completed with 54 participants, primary completion was 66 days ago. Elezanumab targets RGMa to promote neuroregeneration—a mechanistically plausible but unproven approach in acute SCI. The primary endpoint UEMS at 52 weeks is clinically meaningful but SCI trials historically show high placebo response and poor signal-to-noise. The 1:2 randomization (33% placebo) is underpowered for efficacy detection. No prior Phase 1 SCI data is disclosed, increasing uncertainty. AbbVie's silence 66 days post-completion suggests data may be disappointing or complex to interpret, as positive results in orphan indications typically prompt rapid disclosure. The dual primary endpoint structure (efficacy + safety) allows regulatory flexibility but doesn't improve power. Acute intervention window (24 hours) is appropriate but enrollment across 49 sites risks protocol variability. Prior AbbVie neuroscience setbacks (including RGMa programs in MS) temper enthusiasm. Overall, mechanistic promise is offset by small sample, challenging disease biology, and concerning disclosure delay.

Elezanumab is a monoclonal antibody targeting RGMa, an inhibitor of axonal outgrowth. While preclinical data in spinal cord injury (SCI) appeared promising, translating these findings to human SCI has historically proven exceptionally difficult due to the complex, multifaceted inhibitory environment of the human spinal glial scar and significant heterogeneity in spontaneous recovery. The trial's small sample size (N=54, randomized 2:1) makes detecting a statistically significant difference in a noisy clinical outcome like the Upper Extremity Motor Score (UEMS) highly improbable unless the effect size is unprecedented. Furthermore, elezanumab recently failed its Phase 2 trials in multiple sclerosis (RADIUS-R and RADIUS-P), failing to meet primary endpoints and casting doubt on the clinical efficacy of the RGMa inhibition mechanism in humans. Given the notoriously high failure rate in acute SCI trials, the lack of clinical validation for the mechanism, and the severely underpowered nature of this proof-of-concept study for an efficacy readout, the probability of a positive primary efficacy result on UEMS is very low.

The trial is a Phase 2 study evaluating the safety and efficacy of elezanumab in patients with acute traumatic cervical spinal cord injury. The primary endpoint is the Upper Extremity Motor Score (UEMS), a subscore of the International Standards for Neurological Classification of Spinal Cord Injury. Given the mechanism of action of elezanumab as a monoclonal antibody promoting neuroregeneration and the reasonable study design, there is a potential for positive results. However, the small sample size of approximately 54 participants across 49 sites worldwide and the complexity of SCI as an indication introduce uncertainty. The sponsor, AbbVie, is a well-established pharmaceutical company, which adds credibility to the trial. Overall, while there are positive and negative factors, the probability of a positive outcome seems more likely than not.